Stay updated with breaking news from L Dopa. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
An experimental drug that combines low-dose extended-release pramipexole and rasagiline showed strong efficacy in early-stage Parkinson's disease — with less sleepiness — in a new phase 3 trial.
A team of researchers has created a bacteria that can produce a steady and consistent source of medicine inside a patient’s gut, suggesting the possibility for genetically edited bacteria to be an efficient Parkinson’s disease treatment.
Although dopamine agonists and dopamine reuptake inhibitors (DRIs) may be effective in treating Parkinson's disease and motor fluctuations not controlled with levodopa, not all DRIs are equal.
Might statins have detrimental effects on long-term motor and cognitive outcomes in patients with Parkinson's disease?
Explore the unique alterations to gut microbiota which have been identified in Parkinson's disease. What significance might they have as a marker of disease progression or therapeutic target?